Beta-2 Microglobulin Amyloidosis: Past, Present, and Future

Ignacio Portales-Castillo, Jerry Yee, Hiroshi Tanaka, Andrew Z. Fenves

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

Almost half a century has elapsed since the first description of dialysis-related amyloidosis (DRA), a disorder caused by excessive accumulation of β-2 microglobulin (B2M). Within that period, substantial advances in RRT occurred. These improvements have led to a decrease in the incidence of DRA. In many countries, DRA is considered a 'disappearing act' or complication. Although the prevalence of patients living with RRT increases, not all will have access to kidney transplantation. Consequently, the number of patients requiring interventions for treatment of DRA is postulated to increase. This postulate has been borne out in Japan, where the number of patients with ESKD requiring surgery for carpal tunnel continues to increase. Clinicians treating patients with ESKD have treatment options to improve B2M clearance; however, there is a need to identify ways to translate improved B2M clearance into improved quality of life for patients undergoing long-term dialysis.

Original languageEnglish
Pages (from-to)1447-1455
Number of pages9
JournalKidney360
Volume1
Issue number12
DOIs
StatePublished - Dec 1 2020

Keywords

  • advanced glycosylation
  • amyloidosis
  • beta-2-microglobulin
  • carpal tunnel
  • dialysis
  • dialysis
  • hemofiltration
  • microglobulin
  • spondyloarthropathy
  • tenosynovitis

Fingerprint

Dive into the research topics of 'Beta-2 Microglobulin Amyloidosis: Past, Present, and Future'. Together they form a unique fingerprint.

Cite this